Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.

MRD negativity measured by MFC at 3 months after first-line therapy completion in patients with AL amyloidosis is measurable and associated with improved organ response rates and PFS over a long follow-up.